Drug Trial Radar · NCT05112536
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 3, 2022
Primary completion
Oct 31, 2022
Study completion Mar 13, 2023
Sponsor
- Lead sponsor
- G1 Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC). This study will have four phases: 1) Screening Phase, 2) Trilaciclib Lead-In Phase, 3) Treatment Phase, and 4) Surgery and Follow-Up Phase. After a screening phase of up to 21 day, each participant will receive trilaciclib single-dose monotherapy during the lead-in phase, followed by a tumor biopsy. During the treatment phase, each participant will receive trilaciclib with standard of care chemotherapy. Immunotherapy may be included during the treatment phase, per standard of care. 3-5 weeks following conclusion of the treatment phase, each participant will undergo definitive surgery. A 30-day Safety Follow-up Visit will occur 30 days after the last dose of trilaciclib and an End of Study Visit will occur within 14 days after definitive surgery.
Conditions
- Triple Negative Breast Cancer
- Breast Cancer
Interventions
TrilaciclibDrug
Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
CylophosphamideDrug
Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
DoxorubicinDrug
Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
PaclitaxelDrug
Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
Carboplatin (Investigator discretion)Drug
Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
Pembrolizumab (Investigator discretion)Biological
Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immune-based Mechanism of ActionTime frame: Up to 8 days after lead-in trilaciclib dose
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Cancer and Blood Specialty Clinic
Los Alamitos, California
UCLA Department of Medicine - Hematology/Oncology
Santa Monica, California
PIH Health
Whittier, California
Nebraska Hematology-Oncology, P.C.
Lincoln, Nebraska
Duke University Medical Center
Durham, North Carolina
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Virginia Oncology Associates
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.